Active Share (vs S&P 500): 95.4%
· vs QQQ: 99.0%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-11.1%
· vs SPY
-13.2%
· Prev Value $4.97B
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
-4.2%
· vs SPY
-6.3%
· Latest Value $4.91B
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, ORBIMED ADVISORS LLC disclosed 112 equity positions with a combined reported value of $4.91B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were EWTX ($630.05M), VNDA ($482.66M), ELVN ($310.64M). By sector, the heaviest allocations are Health Care 91.9%, Industrials 2.2%. Versus the prior quarter, allocation shifted toward Industrials (+0.7pp) and away from Other (-0.6pp).
Versus the prior quarter, ORBIMED ADVISORS LLC opened 26 new positions, trimmed 32 and fully exited 33, a turnover rate of 62.8% of positions. The portfolio's overlap with the prior quarter was 59% of names.
The largest new positions opened in Q3 2026 were VNDA ($482.66M), GRTX ($77.46M), ABBV ($67.91M).
Of the 33 positions fully exited versus the prior quarter, the largest were DYN ($71.86M), CGON ($69.12M), BSX ($63.30M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.
Investment Approach
ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.
Asset Classes
ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.
Key People
Samuel Isen - Co-founder and Managing Partner
Steven Bloom - Co-founder and Managing Partner
The firm also has several other managing partners and investment professionals
Notable Facts
ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.
This information is based on public disclosures; investment decisions should reference official filings.
AI Rebalance Analysis
1. Overall direction and market view: The fund increased positions (26 new) and total value, with a focus on Health Care (100% of top-10). Weight changes suggest tactical adjustments rather than broad sector rotation.
2. Key moves:
- Added: MRK (+42.6% shares, weight +1.09pp).
- Reduced: MBX (-10.3% shares, weight -0.14pp).
- New: VNDA (9.82% weight).
3. Portfolio structure: Active, concentrated (112 positions), high Health Care bias. Risk appetite appears moderate, with mix of large caps (LLY, MRK) and biotech (EWTX, ELVN).
4. Per-holding one-liner:
- EWTX: Biotech (unverified).
- VNDA: Neurology-focused pharma (unverified).
- ELVN: Biotech (unverified).
- LLY: Large-cap pharma.
- SVA: Vaccines (unverified).
- MBX: Biotech (unverified).
- MRK: Large-cap pharma.
- GH: Cancer diagnostics (unverified).
- AVBP: Biotech (unverified).
- CRVS: Oncology biotech (unverified).
5. Style summary: Tactically added Merck while trimming a small biotech, expanding into new biotech names within a concentrated, Health Care-focused active strategy.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:41
Every 13F share count is marked to the quarter-end close, rebuilding the NAV this
portfolio would have earned had it done nothing all quarter. This is a historical
reconstruction from already-public filings and prices — not a model forecast, so
precision/recall do not apply.
2025-Q3 = 100. Solid = reconstructed NAV, dashed = SPY benchmark.
Prices are split-adjusted closes and exclude dividends, so dividend-heavy
portfolios would in reality sit slightly above this line.
This portfolio is broadly diversified (Top-10 = 43.3% of reported value), so a
Top-10 proxy cannot represent the whole fund — only the full-holdings reconstruction is shown.
Why there is no forecast NAV
Not published because:
Top-10 covers < 85% of reported value · Holdings-forecast backtest F1 < 0.80 · Top-10 quarterly turnover > 20%
Source: full 13F positions marked to quarter-end closes (computed 2026-11-02 01:13:11).
Share counts and prices are used as a ratio, so splits cancel out.
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q3)
P 70%R 70%F1 70%(modelled on 2026-Q2; 7/10 hit)
Low-confidence forecast
This fund replaces about 22% of its Top-10 each quarter and
backtests at F1 78% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-16.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.
Portfolio return-2.18%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+14.84%vs benchmark
Barra annualised vol20.2%Model estimate
Realised vol26.6%Annualised in window
Weighted beta0.58Raw exposure
Factor / specific risk71% / 29%Share of variance
Top-10 concentration73.2%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
-2.18%
Disclosed long book
QQQ synthetic benchmark
-17.01%
Liquidity-weighted constituents
Model universe, equal weight
-1.70%
Opportunity-cost reference
Excess return
+14.84%
Portfolio − benchmark
Arithmetic return sum
-1.74%
Difference vs compounded is the cross term
Weighted raw beta
0.58
Weighted holding betas
Realised volatility (annualised)
26.63%
Daily returns in window
Barra model volatility (annualised)
20.16%
Factor + specific
Factor share of variance
70.9%
Barra factors
Specific share of variance
29.1%
Stock residuals
Reported value
$1.48B
13F long US equity
2. Return attribution
The -1.74% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
+0.43%
24.5%
Momentum & Growth
3
-2.85%
-163.2%
Volatility & Tail Risk
7
+2.16%
123.6%
Industry
12
+6.58%
376.9%
Specific
1
-8.06%
-461.8%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Health Care
Industry
+0.92
+6.98%
+6.42%
368.2%
Kurtosis
Style
+0.47
+7.51%
+3.50%
200.5%
Residual Volatility
Style
+0.82
+3.29%
+2.72%
155.7%
Turnover
Style
-0.36
-4.80%
+1.73%
99.0%
Leverage (Downside Vol)
Style
-0.24
-1.71%
+0.41%
23.3%
Growth
Style
+0.23
+1.75%
+0.40%
22.8%
Non-linear Size
Style
+0.25
+1.01%
+0.25%
14.2%
Consumer Staples
Industry
+0.01
+12.82%
+0.14%
7.8%
Amihud Illiquidity
Style
+0.26
-0.45%
-0.12%
-6.7%
Historical Volatility
Style
+0.01
-14.00%
-0.13%
-7.4%
Short-term Reversal
Style
-0.17
+0.87%
-0.15%
-8.4%
Max Drawdown
Style
+0.26
-1.76%
-0.46%
-26.4%
Beta
Style
-0.29
+4.44%
-1.31%
-74.9%
Mid Cap
Style
+0.77
-1.94%
-1.48%
-85.0%
Skewness
Style
+0.58
-4.39%
-2.57%
-147.2%
Momentum
Style
+0.77
-4.00%
-3.10%
-177.6%
Specific
Specific
—
—
-8.06%
-461.8%
3. Risk attribution
Annualised volatility is 20.16%; factor risk explains 70.9% of variance and specific risk 29.1%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Health Care
Industry
+0.92
51.8%
+10.45%
10.4%
Specific
Specific
—
29.1%
+5.86%
5.9%
Momentum
Style
+0.77
11.2%
+2.25%
2.2%
Mid Cap
Style
+0.77
4.3%
+0.87%
0.9%
Residual Volatility
Style
+0.82
2.0%
+0.41%
0.4%
Industrials
Industry
+0.07
2.0%
+0.40%
0.4%
Kurtosis
Style
+0.47
1.4%
+0.29%
0.3%
Skewness
Style
+0.58
1.2%
+0.24%
0.2%
Growth
Style
+0.23
1.2%
+0.24%
0.2%
Consumer Staples
Industry
+0.01
0.3%
+0.07%
0.1%
Amihud Illiquidity
Style
+0.26
-0.4%
-0.08%
-0.1%
Max Drawdown
Style
+0.26
-0.6%
-0.13%
-0.1%
Short-term Reversal
Style
-0.17
-0.7%
-0.13%
-0.1%
Beta
Style
-0.29
-3.0%
-0.60%
-0.6%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-0.02
+2.10
-2.12
Non-linear Size
+0.24
+1.68
-1.43
Mid Cap
+0.77
+0.13
+0.64
Beta
-0.29
+1.29
-1.59
Momentum
+0.78
+0.72
+0.06
Short-term Reversal
-0.17
-0.64
+0.48
Residual Volatility
+0.82
-0.40
+1.23
Historical Volatility
+0.01
+0.86
-0.85
Liquidity
+0.04
+0.11
-0.08
Amihud Illiquidity
+0.26
+1.16
-0.89
Turnover
-0.36
+0.21
-0.57
Growth
+0.23
+0.58
-0.36
Leverage (Downside Vol)
-0.24
+0.14
-0.38
Skewness
+0.58
+0.24
+0.35
Kurtosis
+0.47
+0.21
+0.25
Max Drawdown
+0.26
-0.08
+0.35
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-22.33%
+3.83%
+16.44%
-16.44%
+16.44%
Communication Services
0.0%
2.6%
+0.00%
-17.64%
+0.01%
+0.46%
-0.46%
+0.46%
Utilities
0.0%
0.8%
+0.00%
+11.13%
-0.22%
-0.09%
+0.09%
-0.09%
Consumer Staples
1.1%
0.8%
+3.38%
+15.26%
+0.07%
-0.10%
-0.03%
-0.09%
Industrials
7.0%
11.1%
+2.60%
+4.36%
-0.89%
-0.20%
+0.07%
-0.30%
Consumer Discretionary
0.0%
8.8%
+0.00%
+3.76%
-1.84%
-0.33%
+0.33%
-0.33%
Health Care
92.0%
1.7%
-1.12%
+8.29%
+22.94%
-0.16%
-8.49%
-1.18%
Total
+23.78%
+16.00%
-24.90%
+14.88%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
LLY
ELI LILLY & CO
Health Care
20.17%
+23.73%
+4.79%
Hold
MRK
MERCK & CO INC
Health Care
9.29%
-0.58%
-0.05%
Add
GH
GUARDANT HEALTH INC
Health Care
7.04%
-19.25%
-1.35%
Hold
AVBP
ARRIVENT BIOPHARMA INC
Health Care
6.20%
-61.82%
-3.83%
Hold
NTRA
NATERA INC
Health Care
5.58%
-30.20%
-1.69%
Reduce
TMO
THERMO FISHER SCIENTIFIC INC
Industrials
5.49%
+2.41%
+0.13%
Add
UNH
UNITEDHEALTH GROUP INC
Health Care
5.43%
+12.24%
+0.66%
Add
ARGX
ARGENX SE
Health Care
4.87%
-0.83%
-0.04%
Reduce
ABBV
ABBVIE INC
Health Care
4.59%
+12.60%
+0.58%
New
ODTX
ODYSSEY THERAPEUTICS INC
Health Care
4.51%
-12.87%
-0.58%
Hold
AZN
ASTRAZENECA PLC
Health Care
4.18%
+13.96%
+0.58%
Reduce
ABT
ABBOTT LABORATORIES
Health Care
3.87%
+8.72%
+0.34%
New
HUM
HUMANA INC
Health Care
3.30%
+20.88%
+0.69%
Reduce
GPCR
STRUCTURE THERAPEUTICS INC
Health Care
2.81%
-40.61%
-1.14%
Reduce
ISRG
INTUITIVE SURGICAL INC
Health Care
2.66%
+7.65%
+0.20%
Reduce
WST
WEST PHARMACEUTICAL SVSC INC
Health Care
2.01%
+12.69%
+0.26%
Add
DXCM
DEXCOM INC
Health Care
1.62%
-5.42%
-0.09%
New
PTGX
PROTAGONIST THERAPEUTICS INC
Health Care
1.43%
-11.40%
-0.16%
Add
WAT
WATERS CORP
Industrials
1.20%
+3.19%
+0.04%
Hold
CVS
CVS HEALTH CORP
Consumer Staples
1.06%
+3.38%
+0.04%
New
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
LLY
Health Care
20.17%
+23.73%
+4.79%
2
HUM
Health Care
3.30%
+20.88%
+0.69%
3
UNH
Health Care
5.43%
+12.24%
+0.66%
4
AZN
Health Care
4.18%
+13.96%
+0.58%
5
ABBV
Health Care
4.59%
+12.60%
+0.58%
6
ABT
Health Care
3.87%
+8.72%
+0.34%
7
WST
Health Care
2.01%
+12.69%
+0.26%
8
ISRG
Health Care
2.66%
+7.65%
+0.20%
9
ODTX
Health Care
4.51%
-12.87%
-0.58%
10
GPCR
Health Care
2.81%
-40.61%
-1.14%
11
GH
Health Care
7.04%
-19.25%
-1.35%
12
NTRA
Health Care
5.58%
-30.20%
-1.69%
13
AVBP
Health Care
6.20%
-61.82%
-3.83%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -2.18%, versus -17.01% for the QQQ synthetic benchmark — an excess of +14.84%.
Return attribution: the largest positive style/industry contributions came from Health Care +6.42%, Kurtosis +3.50%, Residual Volatility +2.72%; the largest drags came from Momentum -3.10%, Skewness -2.57%, Mid Cap -1.48%. Specific (stock-level) return contributed -8.06%.
Risk attribution: Barra model volatility is 20.16% annualised; factor risk explains 71% of variance and specific risk 29%. The largest factor risk sources are Health Care 51.8%, Momentum 11.2%, Mid Cap 4.3%.
Style tilt: size -0.02, momentum +0.78, volatility +0.01, liquidity +0.04; the weighted raw beta is 0.58. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+90.2 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.78%, selection +16.00% and interaction -24.90%.
Concentration: the top-10 positions are 73.2% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did ORBIMED ADVISORS LLC buy in 2026-Q3?
In its 2026-Q3 13F filing, ORBIMED ADVISORS LLC reported 112 equity positions worth $4.91B in aggregate; its largest disclosed positions were EWTX ($630.05M), VNDA ($482.66M), ELVN ($310.64M).
How large is ORBIMED ADVISORS LLC's portfolio?
ORBIMED ADVISORS LLC reported $4.91B of long equity holdings across 112 positions as of 2026-Q3. Top-10 holdings account for 51.1% of reported value.
What is ORBIMED ADVISORS LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>